India Urology Drugs Market, By Drug Class (Anticholinergic/ Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others), By Type (Original Drugs v/s Generic Drugs), By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, Competition Forecast & Opportunities, FY2027
India urology drugs market is anticipated to grow with an estimated CAGR in the forecast years FY2023-FY2027, on the grounds of increasing instances of urology diseases and urinary tract disorders. Increasing advancement in the pharmaceutical industry regarding urinary disease treatment is further driving the growth of the India urology drugs market in the upcoming five years.
Urology drugs are the pharmaceuticals that are used a treatment for urogenital conditions and diseases like urinary inconsistences, prostatic hyperplasia, and erectile dysfunctions. Urology is a part of healthcare sector that deals with the diseases of male and female urinary tract including reproductive organs. Urinary tract includes organs like kidney, ureters, bladder, and urethra. Reproductive organs like penis, testes, scrotum, prostate, etc. involved in the conditions is also treated with use of urology drugs. Advancing pharmaceutical industry is consistently developing various therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), Regurin and Sanctura (trospium chloride), Toviaz (fesoterodine), Vesicare (solifenacin), Sanctura (trospium).
Increasing Instances of Urinary Diseases Drive Market Growth
Rapidly increasing instances of urinary diseases and disorders in the country is anticipated to further drive the growth of the India urology drugs market in the upcoming five years. Approximately, 800 per million population in India have risk of chronic kidney diseases as per the report from 2020. The increasing risk of prostate cancer also supports the growth of the India urology drugs market in the next five years. Prostate cancer is the second leading site of cancer instances in the Indian males in metro cities like Delhi, Kolkata, Pune and Thiruvananthapuram.
Advancing Pharma Industry Supports Market Growth
Rapidly increasing advancement and product development is driving the growth of the India urology drugs market in the upcoming five years. Moreover, increasing investment in the research sector of the drug development is further anticipated to support the growth of the India urology drugs market in the next five years. Recent drug developments like antimuscarinic and beta-3-agonist drugs advances the growth of the India urology drugs market in the future five years.
Also, therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), among other urology drugs are some of the advanced pharmaceutical products that are further substantiating the growth of the India urology drugs market in the forecast years.
Market Segmentation
The India urology drugs market segmentation is based on drug class, type, application, distribution channel, competitional landscape, and regional distribution. Based on drug class, the market is further fragmented into anticholinergic/ antispasmodic agents, skeletal muscle relaxants, alpha blockers, and others. Also based on type, the market is further divided between original drugs and generic drugs. Based on application, the market is segmented into benign prostatic hyperplasia (BPH), prostate cancer, urinary incontinence, kidney/bladder stone, erectile dysfunction, and others. The market segmentation based on distribution channel is bifurcated into hospital pharmacies, retail pharmacies, and online. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North India region, South India region, East India region, and West India region.
Company Profile
Astellas Pharma India Pvt Ltd, Endo Pharmaceuticals, Sanofi India, Pfizer Ltd., Innovexia Lifesciences, Salvus Pharma, Silhos Pharma Ltd., are some of the major market players in the country that lead the market growth analysis. New market players are also actively entering the market in the recent years and further strengthening the growth of the future market growth.
Report Scope:
In this report, India Urology drugs market is segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in India urology drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Urology drugs are the pharmaceuticals that are used a treatment for urogenital conditions and diseases like urinary inconsistences, prostatic hyperplasia, and erectile dysfunctions. Urology is a part of healthcare sector that deals with the diseases of male and female urinary tract including reproductive organs. Urinary tract includes organs like kidney, ureters, bladder, and urethra. Reproductive organs like penis, testes, scrotum, prostate, etc. involved in the conditions is also treated with use of urology drugs. Advancing pharmaceutical industry is consistently developing various therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), Regurin and Sanctura (trospium chloride), Toviaz (fesoterodine), Vesicare (solifenacin), Sanctura (trospium).
Increasing Instances of Urinary Diseases Drive Market Growth
Rapidly increasing instances of urinary diseases and disorders in the country is anticipated to further drive the growth of the India urology drugs market in the upcoming five years. Approximately, 800 per million population in India have risk of chronic kidney diseases as per the report from 2020. The increasing risk of prostate cancer also supports the growth of the India urology drugs market in the next five years. Prostate cancer is the second leading site of cancer instances in the Indian males in metro cities like Delhi, Kolkata, Pune and Thiruvananthapuram.
Advancing Pharma Industry Supports Market Growth
Rapidly increasing advancement and product development is driving the growth of the India urology drugs market in the upcoming five years. Moreover, increasing investment in the research sector of the drug development is further anticipated to support the growth of the India urology drugs market in the next five years. Recent drug developments like antimuscarinic and beta-3-agonist drugs advances the growth of the India urology drugs market in the future five years.
Also, therapeutic drugs like Detrol (tolterodine), Enablex (darifenacin), Oxytrol or Ditropan XL (oxybutynin), among other urology drugs are some of the advanced pharmaceutical products that are further substantiating the growth of the India urology drugs market in the forecast years.
Market Segmentation
The India urology drugs market segmentation is based on drug class, type, application, distribution channel, competitional landscape, and regional distribution. Based on drug class, the market is further fragmented into anticholinergic/ antispasmodic agents, skeletal muscle relaxants, alpha blockers, and others. Also based on type, the market is further divided between original drugs and generic drugs. Based on application, the market is segmented into benign prostatic hyperplasia (BPH), prostate cancer, urinary incontinence, kidney/bladder stone, erectile dysfunction, and others. The market segmentation based on distribution channel is bifurcated into hospital pharmacies, retail pharmacies, and online. The market analysis also studies the regional segmentation to devise regional market segmentation, divided among North India region, South India region, East India region, and West India region.
Company Profile
Astellas Pharma India Pvt Ltd, Endo Pharmaceuticals, Sanofi India, Pfizer Ltd., Innovexia Lifesciences, Salvus Pharma, Silhos Pharma Ltd., are some of the major market players in the country that lead the market growth analysis. New market players are also actively entering the market in the recent years and further strengthening the growth of the future market growth.
Report Scope:
In this report, India Urology drugs market is segmented into following categories, in addition to the industry trends which have also been detailed below:
- India Urology Drugs Market, By Drug Class:
- Anticholinergic/ Antispasmodic Agents
- Skeletal Muscle Relaxants
- Alpha Blockers
- Others
- India Urology Drugs Market, By Type:
- Original Drugs
- Generic Drugs
- India Urology Drugs Market, By Application:
- Benign Prostatic Hyperplasia (BPH)
- Prostate Cancer
- Urinary Incontinence
- Kidney/Bladder Stone
- Erectile Dysfunction
- Others
- India Urology Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online
- India Urology Drugs Market, By Region:
- South
- West
- North
- East
Company Profiles: Detailed analysis of the major companies present in India urology drugs market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON INDIA UROLOGY DRUGS MARKET
4. EXECUTIVE SUMMARY
5. VOICE OF CUSTOMERS
6. INDIA UROLOGY DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume (Thousand Units)
6.2. Market Share & Forecast
6.2.1. By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others)
6.2.2. By Type (Original Drugs v/s Generic Drugs)
6.2.3. By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
6.2.5. By Company (FY2021)
6.2.6. By Region
6.2.6.1. By State (Top 3 States)
6.3. Product Market Map
7. INDIA ANTICHOLINERGIC/ANTISPASMODIC UROLOGICAL AGENTS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume (Thousand Units)
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Distribution Channel
8. INDIA SKELETAL MUSCLE RELAXANTS UROLOGY DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume (Thousand Units)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Distribution Channel
9. INDIA ALPHA BLOCKERS UROLOGY DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume (Thousand Units)
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Distribution Channel
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
12. POLICY & REGULATORY LANDSCAPE
13. PRICING ANALYSIS
14. IMPORT-EXPORT ANALYSIS
15. INDIA ECONOMIC PROFILE
16. COMPETITIVE LANDSCAPE
16.1. Competition Outlook
16.2. Company Profiles
16.2.1. Detailed Analysis of Marketing Activities of Top 3 Players Profiles
16.2.1.1. Astellas Pharma India Pvt Ltd
16.2.1.2. Endo Pharmaceuticals
16.2.1.3. Sanofi India
16.2.1.4. Pfizer Ltd.
16.2.1.5. Innovexia Lifesciences
16.2.1.6. Salvus Pharma
16.2.1.7. Silhos Pharma Ltd.
17. GO-TO-MARKET STRATEGIES (COVERS DETAILED ANALYSIS OF STRATEGIES TO BE FOLLOWED FOR MAKING MARKET ENTRY, WHAT COMPETITORS ARE DOING, ETC.)
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
(The company names can be customized according to the client’s requirements)
2. RESEARCH METHODOLOGY
3. IMPACT OF COVID-19 ON INDIA UROLOGY DRUGS MARKET
4. EXECUTIVE SUMMARY
5. VOICE OF CUSTOMERS
6. INDIA UROLOGY DRUGS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume (Thousand Units)
6.2. Market Share & Forecast
6.2.1. By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Alpha Blockers, Others)
6.2.2. By Type (Original Drugs v/s Generic Drugs)
6.2.3. By Application (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Urinary Incontinence, Kidney/Bladder Stone, Erectile Dysfunction, Others)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
6.2.5. By Company (FY2021)
6.2.6. By Region
6.2.6.1. By State (Top 3 States)
6.3. Product Market Map
7. INDIA ANTICHOLINERGIC/ANTISPASMODIC UROLOGICAL AGENTS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume (Thousand Units)
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Distribution Channel
8. INDIA SKELETAL MUSCLE RELAXANTS UROLOGY DRUGS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume (Thousand Units)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Distribution Channel
9. INDIA ALPHA BLOCKERS UROLOGY DRUGS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume (Thousand Units)
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Distribution Channel
10. MARKET DYNAMICS
10.1. Drivers
10.2. Challenges
11. MARKET TRENDS & DEVELOPMENTS
12. POLICY & REGULATORY LANDSCAPE
13. PRICING ANALYSIS
14. IMPORT-EXPORT ANALYSIS
15. INDIA ECONOMIC PROFILE
16. COMPETITIVE LANDSCAPE
16.1. Competition Outlook
16.2. Company Profiles
16.2.1. Detailed Analysis of Marketing Activities of Top 3 Players Profiles
16.2.1.1. Astellas Pharma India Pvt Ltd
16.2.1.2. Endo Pharmaceuticals
16.2.1.3. Sanofi India
16.2.1.4. Pfizer Ltd.
16.2.1.5. Innovexia Lifesciences
16.2.1.6. Salvus Pharma
16.2.1.7. Silhos Pharma Ltd.
17. GO-TO-MARKET STRATEGIES (COVERS DETAILED ANALYSIS OF STRATEGIES TO BE FOLLOWED FOR MAKING MARKET ENTRY, WHAT COMPETITORS ARE DOING, ETC.)
18. STRATEGIC RECOMMENDATIONS
19. ABOUT US & DISCLAIMER
(The company names can be customized according to the client’s requirements)
